Company intelligence / Profile preview

Bolder BioTechnology

Boulder, Colorado, United Statesbolderbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Bolder BioTechnology has demonstrated positive Phase 1 results for its lead candidate BBT‑015—a long‑acting G-CSF analog—showing increased potency and safety in healthy volunteers. Other programs are at preclinical or research stages targeting large markets with unmet needs.

Therapeutic areas: OncologyEndocrinologyHematologyNeurologyInfectious Diseases
Modalities: Long-acting human protein pharmaceuticals (engineered proteins, including analogs of G-CSF, IL-11, alpha interferon)
Industry: Biotech

Drug pipeline

11 assets

BBT-059

Preclinical

10 more assets in the full pipeline.

Request access →

Partnerships

Strategic alliances with corporate partners intended for commercialization but no specific partners named publicly as of now

Beyond the preview

Go deeper on Bolder BioTechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bolder BioTechnology.

Explore the full profile